2017

150.00 rub.
Buy article
2017/№3

Efficiency of rivaroxaban in a patient with myocardial infarction and left ventricular thrombus

Beyshenkulov M. T., Usupbaeva D. A., Kaliev K. R., Chazymova Z. M., Abdurashidova T. Sh., Toktosunova A. K.
National Center of Cardiology and Internal Medicine Kyrgyz Republic, Togolok Moldo str. 3, Bishkek 720040, Kyrgyz Republic

Keywords: warfarin, rivaroxaban

DOI: 10.18087/rhj.2017.3.2364

The article presents a clinical case of efficient rivaroxaban treatment in addition to dual antiplatelet therapy for LV cavity postinfarction thrombus in a patient who had undergone a transcutaneous coronary intervention.
  1. Weinsaft JW, Kim J, Medicherla CB, Ma CL, Codella NCF, Kukar N et al. Echocardiographic Algorithm for Post-Myocardial Infarction LV Thrombus: A Gatekeeper for Thrombus Evaluation by Delayed Enhancement CMR . JACC Cardiovasc Imaging. 2016;9(5):505–15. DOI:10.1016/j.jcmg.2015.06.017.
  2. O’Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, de Lemos JA et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology. 2013;61(4):e78–140. DOI:10.1016/j.jacc.2012.11.019.
  3. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33(20):2569–619. DOI:10.1093/eurheartj/ehs215.
  4. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013;15(5):625–51. DOI:10.1093/europace/eut083.
  5. Harder S. Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism. Thromb J. 2014;12:22. DOI:10.1186/1477-9560-12-22.
  6. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18(11):1609–78. DOI:10.1093/europace/euw295.
  7. Saar JA, Maack C, European Society of Cardiology. [Diagnosis and management of acute pulmonary embolism. ESC guidelines 2014]. Herz. 2015;40(8):1048–54. DOI:10.1007/s00059-015-4378-0.
  8. Azizi A, Puricel S, Cook S, Brugger N. Rivaroxaban dissolves postinfarction left ventricular thrombus. Cardiovascular Medicine. 2016;19(1):25–7.
  9. Nagamoto Y, Shiomi T, Matsuura T, Okahara A, Takegami K, Mine D et al. Resolution of a left ventricular thrombus by the thrombolytic action of dabigatran. Heart Vessels. 2014;29(4):560–2. DOI:10.1007/s00380-013-0403-5.
  10. Nakasuka K, Ito S, Noda T, Hasuo T, Sekimoto S, Ohmori H et al. Resolution of left ventricular thrombus secondary to tachycardia-induced heart failure with rivaroxaban. Case Rep Med. 2014;2014:814524. DOI:10.1155/2014/814524.
  11. Las Casas AA, Las Casas AA, Borges MAF, Melo-Souza SE. Rivaroxaban for treatment of intraventricular thrombus in Chagas disease. Journal of Cardiology Cases. 2016;13(3):75–7. DOI:10.1016/j.jccase.2015.10.010.
  12. Padilla Pérez M, Salas Bravo D, Garcelán Trigo JA, Vazquez Ruiz de Castroviejo E, Torres Llergo J, Lozano Cabezas C et al. Resolution of left ventricular thrombus by rivaroxaban. Future Cardiol. 2014;10(3):333–6. DOI:10.2217/fca.14.12.
  13. Hammerstingl C, Pötzsch B, Nickenig G. Resolution of giant left atrial appendage thrombus with rivaroxaban. Thromb Haemost. 2013;109(4):583–4. DOI:10.1160/TH12-11-0821.
  14. Kolh P, Windecker S, Alfonso F, Collet J-P, Cremer J, Falk V et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg. 2014;46(4):517–92. DOI:10.1093/ejcts/ezu366.
  15. Sarafoff N, Martischnig A, Wealer J, Mayer K, Mehilli J, Sibbing D et al. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. J Am Coll Cardiol. 2013;61(20):2060–6. DOI:10.1016/j.jacc.2013.02.036.
Beyshenkulov M. T., Usupbaeva D. A., Kaliev K. R., Chazymova Z. M., Abdurashidova T. Sh., Toktosunova A. K. Efficiency of rivaroxaban in a patient with myocardial infarction and left ventricular thrombus. Russian Heart Journal. 2017;16 (3):213–215

To access this material please log in or register

Register Authorize
Ru En